Lowering LDL cholesterol through statin-based treatment did not slow kidney disease progression within five years in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The ...
May 1, 2014
0
0
Heart attacks among adults younger than 50 years of age are on the rise. In fact, the proportion of very young people has been increasing, rising by 2 percent each year for the last 10 years, according to a team of investigators ...
May 21, 2019
0
0
Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia—elevations of triglycerides and cholesterol.
May 28, 2024
0
33
New research shows that women undergoing percutaneous coronary intervention (PCI), also known as angioplasty, exhibit more co-morbidities and cardiovascular risk factors than men. Risk-adjusted analyses have now indicated ...
Nov 1, 2011
0
0
A study from an international research team finds that familial hypercholesterolemia (FH) - a genetic condition that causes greatly elevated levels of LDL cholesterol throughout life - accounts for less than 2 percent of ...
Apr 3, 2016
0
3
The Family Heart Foundation, a leading research and advocacy organization, has shared results from an analysis of patients in its CASCADE FH Registry showing that children with homozygous familial hypercholesterolemia (HoFH) ...
Oct 11, 2022
0
6
Drug targets with human genetic evidence are more likely than those without to be clinically translatable and thus enter phase II/III clinical trials or be approved for marketing more quickly, which will likely significantly ...
Mar 26, 2024
0
0
(HealthDay)—Serum 25-hydroxyvitamin D [25(OH)D] is independently and inversely associated with total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol in children, according ...
Aug 16, 2018
0
5
US experts urged regulators Wednesday to approve a second new anti-cholesterol drug, a day after recommending they bring to market the first in a new class of medications to lower the risk of heart attack.
Jun 10, 2015
0
11
(HealthDay)—Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) may help assess apparent resistance to PCSK9 inhibitors, according to a research letter published online Nov. 28 in the Annals of Internal ...
Nov 29, 2017
0
19
